[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444432":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":39,"responsibleParty":131,"collaborators":25,"id":133,"slug":25,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":134,"sex":140,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":25,"studyType":146,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":74,"whyStopped":25,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Tang-Du Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tocilizumab","EXPERIMENTAL","Participants will receive tocilizumab administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.",[13],"Drug: Tocilizumab Injectable Product",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive placebo administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tocilizumab Injectable Product","Participants will receive IV tocilizumab",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Ting Chang, MD,PHD","The Second Affiliated Hospital of Air Force Military Medical University","STUDY_DIRECTOR",[32,36],{"name":28,"role":33,"phone":34,"phoneExt":25,"email":35},"CONTACT","+86-29-84778845","changting1981@163.com",{"name":37,"role":33,"phone":34,"phoneExt":25,"email":38},"Zhe Ruan","ruanzhe573291596@126.com",[40,58,72,88,103,117],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Beijing Tiantan Hospital, Capital Medical University","NOT_YET_RECRUITING","Beijing","Beijing Municipality","100050","China",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":56,"phoneExt":25,"email":57},"Fudong Shi, MD,PHD","+86-22-60817429","fshi@tmu.edu.cn",{"facility":59,"status":42,"city":60,"state":61,"zip":62,"country":46,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Xiangya Hospital Central South University","Changsha","Hunan","410008",{"type":48,"coordinates":64},[65,66],112.97087,28.19874,{"lat":66,"lon":65},[69],{"name":70,"role":33,"phone":25,"phoneExt":25,"email":71},"Huan Yang, MD,PHD","yxyx69@gahoo.com.cn",{"facility":73,"status":74,"city":75,"state":76,"zip":77,"country":46,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Tangdu Hospital, The Fourth Military Medical University","RECRUITING","Xi'an","Shaanxi","710038",{"type":48,"coordinates":79},[80,81],108.92861,34.25833,{"lat":81,"lon":80},[84,87],{"name":85,"role":33,"phone":86,"phoneExt":25,"email":35},"Ting Chang","02984778845",{"name":37,"role":33,"phone":25,"phoneExt":25,"email":38},{"facility":89,"status":42,"city":90,"state":91,"zip":92,"country":46,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Huashan Hospital","Shanghai","Shanghai Municipality","200040",{"type":48,"coordinates":94},[95,96],121.45806,31.22222,{"lat":96,"lon":95},[99],{"name":100,"role":33,"phone":101,"phoneExt":25,"email":102},"Chongbo Zhao, MD,PHD","86-21-52889999","zhao_chongbo@fudan.edu.cn",{"facility":104,"status":42,"city":105,"state":106,"zip":107,"country":46,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"West China Hospital of Sichuan University","Chengdu","Sichuan","610041",{"type":48,"coordinates":109},[110,111],104.06667,30.66667,{"lat":111,"lon":110},[114],{"name":115,"role":33,"phone":25,"phoneExt":25,"email":116},"Hongyu Zhou, MD,PHD","zhouhy@scu.edu.cn",{"facility":118,"status":42,"city":119,"state":120,"zip":121,"country":46,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Tianjin medical university general hospital","Tianjin","Tianjin Municipality","300052",{"type":48,"coordinates":123},[124,125],117.17667,39.14222,{"lat":125,"lon":124},[128],{"name":129,"role":33,"phone":130,"phoneExt":25,"email":25},"Chao Zhang, MD,PHD","+86-22-60362255",{"type":132,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100444432",false,"NCT05067348","Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis","A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis","tMG","Inclusion Criteria:\n\n1. Diagnosis of MG with anti-AChRantibody.\n2. MGFA Clinical Classification Class II, III, or IV.\n3. MG-ADL score of 5 or greater at screening and at randomization with \\> 50% of this score attributed to non-ocular items.\n4. QMG score of 11 or greater.\n5. Subjects must be on:\n\n   1. Cholinesterase inhibitor, with no dose increase within 4 weeks prior to randomization;\n   2. Corticosteroids, with no dose increase within 4 weeks prior to randomization; or\u002Fand c. non-steroidal IST (including azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A), with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization.\n\nExclusion Criteria:\n\n1. Participants had clinically relevant active infections (such as sepsis, pneumonia, or abscess) or severe infections (resulting in hospitalization or requiring antibiotic treatment) in the 4 weeks before randomization;\n2. Those with a history of high-risk tuberculosis infection, acquired tuberculosis infection, and chronic hepatitis;\n3. Human immunodeficiency virus (HIV) infection;\n4. Thymomas that have received thymectomy or planned thymectomy during RCP within 6 months before randomization, or require chemotherapy and\u002For radiotherapy at any time;\n5. Received rituximab treatment in the past 6 months before randomization;\n6. Received tocilizumab or eculizumab treatment within 3 months before randomization;\n7. Received IVIG or plasma exchange within 4 weeks before randomization;\n8. Unresected thymoma.\n9. History of other tumor diseases.","ALL","18 Years","80 Years",{"count":144,"type":145},64,"ESTIMATED","INTERVENTIONAL",[148],"PHASE2","Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.",[151],"Myasthenia Gravis, Generalized",[153,9],"Generalized Myasthenia Gravis","2025-04-28",{"date":156,"type":157},"2025-05-01","ACTUAL",{"date":159,"type":157},"2022-07-21",{"date":161,"type":145},"2026-03-30",{"name":5,"class":6},6]